Novartis (NYSE:NVS) Receives “Hold” Rating from Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reiterated their hold rating on shares of Novartis (NYSE:NVS) in a research note issued to investors on Friday, MarketBeat reports.

Other research analysts also recently issued research reports about the stock. The Goldman Sachs Group assumed coverage on shares of Novartis in a research report on Thursday, May 30th. They issued a buy rating and a $120.00 price objective for the company. BMO Capital Markets lifted their price objective on shares of Novartis from $114.00 to $116.00 and gave the company a market perform rating in a research report on Wednesday, April 24th. Barclays raised shares of Novartis to a strong sell rating in a research report on Monday, June 24th. Finally, Jefferies Financial Group lifted their target price on shares of Novartis from $121.00 to $122.50 and gave the stock a buy rating in a report on Tuesday, July 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novartis presently has an average rating of Hold and a consensus price target of $118.13.

Novartis Stock Up 2.5 %

Novartis stock opened at $108.75 on Friday. The company has a market cap of $222.29 billion, a P/E ratio of 14.68, a price-to-earnings-growth ratio of 1.63 and a beta of 0.57. Novartis has a 1-year low of $92.19 and a 1-year high of $112.48. The company has a fifty day simple moving average of $105.49 and a 200 day simple moving average of $102.22. The company has a current ratio of 0.90, a quick ratio of 0.71 and a debt-to-equity ratio of 0.43.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Thursday, July 18th. The company reported $1.97 EPS for the quarter, beating analysts’ consensus estimates of $1.87 by $0.10. Novartis had a net margin of 33.76% and a return on equity of 34.63%. The company had revenue of $12.87 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter last year, the firm posted $1.83 EPS. Research analysts anticipate that Novartis will post 7.37 earnings per share for the current fiscal year.

Institutional Trading of Novartis

Several hedge funds and other institutional investors have recently modified their holdings of NVS. Private Ocean LLC acquired a new stake in Novartis in the 1st quarter worth about $25,000. Frazier Financial Advisors LLC acquired a new stake in Novartis in the 4th quarter worth about $26,000. Richardson Financial Services Inc. acquired a new stake in Novartis in the 4th quarter worth about $26,000. Clearstead Trust LLC raised its stake in Novartis by 73.5% in the 1st quarter. Clearstead Trust LLC now owns 269 shares of the company’s stock worth $26,000 after purchasing an additional 114 shares in the last quarter. Finally, Lynx Investment Advisory acquired a new position in shares of Novartis in the 2nd quarter valued at approximately $29,000. Institutional investors own 13.12% of the company’s stock.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.